Digitoxin Reduces Mortality and Hospitalizations in Heart Failure with Reduced Ejection Fraction: NEJM
Heart failure with reduced ejection fraction (HFrEF) remains a leading cause of morbidity and mortality worldwide, despite advances in guideline-directed medical therapy. Novel or adjunctive pharmacologic interventions are continuously explored to improve clinical outcomes, including reductions in hospitalizations and mortality. Digitoxin, a cardiac glycoside, has long been used for heart failure and atrial arrhythmias, but […]